Search alternatives:
nn decrease » _ decrease (Expand Search), gy decreased (Expand Search), b1 decreased (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
e decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
nn decrease » _ decrease (Expand Search), gy decreased (Expand Search), b1 decreased (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
e decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
-
17941
-
17942
image2_Nuclear Factor Erythroid 2 Related Factor 2 Activator JC-5411 Inhibits Atherosclerosis Through Suppression of Inflammation and Regulation of Lipid Metabolism.tif
Published 2020“…JC-5411 treatment significantly increased the protein expression of Nrf2 and its downstream target gene hemeoxygenase 1 (HO-1) in liver of apolipoprotein E deficient (ApoE<sup>−/−</sup>) mice. …”
-
17943
image2_Nuclear Factor Erythroid 2 Related Factor 2 Activator JC-5411 Inhibits Atherosclerosis Through Suppression of Inflammation and Regulation of Lipid Metabolism.tif
Published 2020“…JC-5411 treatment significantly increased the protein expression of Nrf2 and its downstream target gene hemeoxygenase 1 (HO-1) in liver of apolipoprotein E deficient (ApoE<sup>−/−</sup>) mice. …”
-
17944
image2_Nuclear Factor Erythroid 2 Related Factor 2 Activator JC-5411 Inhibits Atherosclerosis Through Suppression of Inflammation and Regulation of Lipid Metabolism.tif
Published 2020“…JC-5411 treatment significantly increased the protein expression of Nrf2 and its downstream target gene hemeoxygenase 1 (HO-1) in liver of apolipoprotein E deficient (ApoE<sup>−/−</sup>) mice. …”
-
17945
image2_Nuclear Factor Erythroid 2 Related Factor 2 Activator JC-5411 Inhibits Atherosclerosis Through Suppression of Inflammation and Regulation of Lipid Metabolism.tif
Published 2020“…JC-5411 treatment significantly increased the protein expression of Nrf2 and its downstream target gene hemeoxygenase 1 (HO-1) in liver of apolipoprotein E deficient (ApoE<sup>−/−</sup>) mice. …”
-
17946
-
17947
Receiver operating characteristic (ROC) curves.
Published 2023“…The optimal cut-off point of the CD4<sup>+</sup> count was 50 Nr/μl or less. Among the 350 patients received both fungal culture and Mp1p antigen detection, 95/350 (27.1%) patients were culture-positive for a <i>Talaromyces marneffei</i>, 75/350 (21.4%) patients were Mp1p antigen positive. …”
-
17948
Cut-point analysis using Youden’s J Index.
Published 2023“…The optimal cut-off point of the CD4<sup>+</sup> count was 50 Nr/μl or less. Among the 350 patients received both fungal culture and Mp1p antigen detection, 95/350 (27.1%) patients were culture-positive for a <i>Talaromyces marneffei</i>, 75/350 (21.4%) patients were Mp1p antigen positive. …”
-
17949
-
17950
-
17951
-
17952
Young aphasia case study: Source localisation results of the context effect (constrained vs unconstrained naming) in A. and control
Published 2022“…Corresponding Cohen’s d maps (bottom two rows) for control (third row) and A. (fourth row) were thresholded at ±0.2. …”
-
17953
Preparation of Heat-Denatured Macroaggregated Albumin for Biomedical Applications Using a Microfluidics Platform
Published 2021“…These microparticles are formed by heat-denaturing albumin in a bulk solution, making it very challenging to control the size and dispersity of the preparations (coefficient of variation, CV, ∼50%). …”
-
17954
Preparation of Heat-Denatured Macroaggregated Albumin for Biomedical Applications Using a Microfluidics Platform
Published 2021“…These microparticles are formed by heat-denaturing albumin in a bulk solution, making it very challenging to control the size and dispersity of the preparations (coefficient of variation, CV, ∼50%). …”
-
17955
<i>WDR5</i> Expression Is Prognostic of Breast Cancer Outcome
Published 2015“…<div><p>WDR5 is a core component of the human mixed lineage leukemia-2 complex, which plays central roles in ER positive tumour cells and is a major driver of androgen-dependent prostate cancer cell proliferation. …”
-
17956
-
17957
-
17958
DataSheet1_Effect of Urate-Lowering Therapy on the Progression of Kidney Function in Patients With Asymptomatic Hyperuricemia: A Systematic Review and Meta-Analysis.docx
Published 2022“…ULT did not ameliorate eGFR slopes (WMD 0.36 ml/min/1.73 m<sup>2</sup> per year, 95% CI: −0.31, 1.04), or lead to reductions in kidney events (RR 1.26; 95% CI: 0.80, 2.00) or all-cause mortality (RR 1.00; 95% CI: 0.65, 1.55), although ULT resulted in a decrease in serum uric acid levels (WMD −2.73 mg/dl; 95% CI: −3.18, −2.28) and lowered the incidence of gout episodes (0.9 vs 2.7%, RR 0.38; 95% CI: 0.17, 0.86).…”
-
17959
-
17960
Recurrence risk assessment of LARC patients undergoing nCRT by ctDNA monitoring.
Published 2021Subjects: